Ampio Pharma (AMPE) Announces Publication of Peer-Review Manuscript on Ampion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Ampio Reports Peer-Reviewed Publication on the Potential use of Ampion™ in New Clinical Indications
September 8, 2016 12:08 PM EDTENGLEWOOD, Colo., Sept. 8, 2016 /PRNewswire/ --Â Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced today publication of a scientific peer-reviewed manuscript in the journal Biochemical Biophysical Research Communications entitled: "The low molecular weight fraction of commercial human serum albumin induces acetylation of -tubulin and reduces transcytosis in retinal endothelial cells."... More
